Hepatitis C, from screening to treatment, a revolution

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) transmission has shifted from blood transfusions to intravenous drug use and, notably, sexual transmission among men who have sex with men (MSM), particularly in HIV-positive individuals.
• Previous treatments like Peg-interferon and ribavirin showed limited efficacy in HIV-positive patients.
• The HCV epidemic remains a significant global health challenge, despite harm reduction strategies.

Purpose of the Study:

• To highlight the significant advancements in hepatitis C virus (HCV) treatment.
• To discuss the impact of new direct antiviral agents (DAAs) on HCV eradication.
• To address the challenges of HCV treatment access and its potential to curb the epidemic.

Main Methods:

• Review of recent developments in HCV research, focusing on new antiviral targets.
• Analysis of the efficacy and tolerability of newly developed direct antiviral agents (DAAs).
• Examination of treatment outcomes in diverse patient populations, including those with HIV co-infection.

Main Results:

• New DAAs demonstrate high efficacy, achieving over 90% HCV eradication rates.
• These treatments are well-tolerated, administered daily for short durations, and effective regardless of prior treatment or comorbidities like HIV.
• Significant progress has been made in identifying novel targets within the HCV replication cycle.

Conclusions:

• Direct antiviral agents represent a transformative approach to HCV treatment, offering a potential cure.
• Broad access to these new therapies is essential to control and potentially eliminate the HCV epidemic.
• Ensuring equitable access in resource-constrained settings presents a critical future challenge.